Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Portal-Systemic Encephalopathy Clinical Presentation

  • Author: Gagan K Sood, MD; Chief Editor: BS Anand, MD  more...
 
Updated: Dec 18, 2014
 

History

The patient may present with vague complaints, such as fatigue, or they may be brought for evaluation by relatives. Indeed, the family members of patients often are the most useful historians. They may describe restlessness (especially at night), somnolence (typically during the day), and instances reflecting episodic confusion.

  • No neurologic features are entirely specific for this disorder.
  • Clinical history or physical examination findings suggestive of liver disease, without evidence of another etiology for neurological dysfunction, form the basis for the diagnosis.
  • A precipitating factor identified from the clinical history strongly suggests the diagnosis. Therefore, directed questioning in this regard is essential.
  • Several predisposing conditions also may contribute to the development of chronic portosystemic encephalopathy.
Next

Physical

As with many toxic and metabolic encephalopathies, mental status and, in particular, level of consciousness may fluctuate dramatically. In addition to impairment of the level of consciousness, patients with portosystemic encephalopathy may demonstrate a variety of neurologic signs together or in isolation.

  • The grades of portosystemic encephalopathy are as follows:
    • Subclinical portosystemic encephalopathy: Early in the course of portosystemic encephalopathy, patients may appear normal clinically but perform poorly on psychometric testing. This is termed subclinical portosystemic encephalopathy. This condition may be particularly important to diagnose in patients performing tasks that require rapid reaction times because these are prolonged in patients with subclinical portosystemic encephalopathy. Judgment also may be erratic or questionable. Recognition of subtle impairment, therefore, may lead to a recommendation to avoid driving an automobile or operating machinery.
    • Grade 1 portosystemic encephalopathy: With deterioration to grade 1 portosystemic encephalopathy, the examination reveals difficulty with memory, mild confusion, agitation, and irritability. Patient complaints may include restlessness or sleeping during the day and remaining awake at night. Tremor, a rhythmic or regular oscillation, and incoordination may be seen. Handwriting skills typically are impaired. Constructional apraxia may be easily demonstrated at the bedside by requesting the patient to draw a 5-pointed star.
    • Grade 2 portosystemic encephalopathy: Progression to grade 2 portosystemic encephalopathy involves a slowing of mentation and speech, with the appearance of lethargy. The patient's confusion progresses to difficulty with orientation to time, and loss of inhibition ultimately may result in inappropriate behavior. Neurologic signs include asterixis and an irregular flapping tremor that is observed best with the wrists dorsiflexed and fingers spread. Dysarthria, ataxia, and hypoactive deep-tendon reflexes are characteristic.
    • Grade 3 portosystemic encephalopathy: This grade portends the significant possibility of coma; therefore, plans to perform endotracheal intubation should be made upon recognition of this state. Patients are drowsy but can be woken up; however, they remain markedly confused. They may exhibit frankly aggressive behavior. Asterixis persists, but the deep-tendon reflexes become hyperactive as they are disinhibited, a process that culminates in the development of the decerebration seen in grade 4. Babinski signs may be seen.
    • Grade 4 portosystemic encephalopathy: This also is known as hepatic coma and represents a medical emergency. Patients are able to protect their airway reliably. Prophylactic endotracheal intubation is mandatory. Patients may remain unresponsive for several days.
  • Stigmata of chronic liver disease and portal hypertension may be evident upon examination. These include the presence of gynecomastia and testicular atrophy in males, palmar erythema, spider nevi, splenomegaly, caput medusae, ascites, peripheral edema, and a shrunken liver.
  • More specific signs resulting from the underlying liver diseases also may be present, as follows:
    • The Kayser-Fleischer rings of Wilson disease typically are identified only with slit-lamp examination.
    • Bronzed skin and arthropathy are seen in hereditary hemochromatosis.
    • Cholesterol deposition may be seen as xanthelasma in patients with chronic cholestasis of any cause, but it often is most striking in primary biliary cirrhosis.
    • Alcoholic liver disease frequently is accompanied by advanced malnutrition; however, any long-standing liver disease also may lead to temporal, shoulder girdle, and hip girdle muscle wasting.
    • Cutaneous features of hepatitis C virus infection include a characteristic rash due to leukocytoclastic vasculitis resulting from mixed cryoglobulinemia, porphyria cutanea tarda, and lichen planus.
Previous
Next

Causes

Precipitating factors that lead to clinical manifestations of portosystemic encephalopathy may be obvious; however, often a cause is not evident despite concerted efforts to identify one. The importance of trying to determine the precipitating cause cannot be overemphasized. Infection, specifically SBP, is especially important to exclude. Several known causes are categorized below by their proposed mechanisms. In some cases, multiple mechanisms may be responsible.

  • Increased ammoniagenesis
    • Increased substrate (protein) for ammoniagenesis
    • Increased protein intake
    • Gastrointestinal bleeding
    • Constipation
    • Dehydration
    • Increased substrate (urea) for ammoniagenesis
    • Renal failure
    • Increased catabolism of protein
    • Infection
    • Hypokalemia
    • Sepsis
  • Decreased hepatocellular function
    • Dehydration
    • Hypotension
    • Sepsis
    • Hypoxia
    • Anemia
    • Development of hepatocellular carcinoma
    • Worsened intrinsic liver disease
    • Drug toxicity
    • Superimposed viral hepatitis
  • Increased portocaval shunting
    • Portal vein thrombosis
    • Transjugular intrahepatic portosystemic shunt formation
    • Surgical shunt formation
    • Spontaneous shunt formation
  • Psychoactive drug use
    • Benzodiazepines
    • Ethanol
    • Antinauseants
    • Antihistamines
    • Others
  • Other mechanisms
    • Increased diffusion of ammonia across the blood-brain barrier: Alkalosis may occur, which promotes ammonium ion conversion to less polar and more diffusible ammonia.
    • Blood transfusion: Increased ammoniagenesis from transfusions may not be entirely accurate and possibly is a more theoretical than practical concern. Glutaminase activity and generation of ammonia in stored cellular blood products (especially platelets) may conceivably lead to infusion of ammonia during transfusion.
Previous
 
 
Contributor Information and Disclosures
Author

Gagan K Sood, MD Associate Professor, Department of Medicine and Surgery, Baylor College of Medicine

Gagan K Sood, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American Gastroenterological Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Noel Williams, MD, FRCPC FACP, MACG, Professor Emeritus, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Professor, Department of Internal Medicine, Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada

Noel Williams, MD, FRCPC is a member of the following medical societies: Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Chief Editor

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Additional Contributors

Ann Ouyang, MBBS Professor, Department of Internal Medicine, Pennsylvania State University College of Medicine; Attending Physician, Division of Gastroenterology and Hepatology, Milton S Hershey Medical Center

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous coauthor, Blake A Jones, MD, to the development and writing of this article.

References
  1. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010. 362(12):1071-1081.

  2. Mullen KD, Poordad F, Rossaro L, et al. Long term efficacy and survival in patients treated with the gut-selective antibiotic rifaximin (550 mg BID) for the maintenance of remission from overt hepatic encephalopathy. Gastroenterol Hepatol. 2011. 7(6 Suppl 9):1-15.

  3. McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev. 2011. (11):CD008716. [Medline].

  4. Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open-Label, Randomized Controlled Trial of Lactulose, Probiotics, and No Therapy. Am J Gastroenterol. 2012 Jun 19. [Medline].

  5. Pockros P, Hassanein T, Vierling J, et al. Phase 2, multicenter, randomized study of AST-120 (spherical carbon adsorbent) vs. lactulose in the treatment of lowgrade hepatic encephalopathy. J Hepatol. 2009. 50(Suppl 1):S43-4.

  6. Simón-Talero M, García-Martínez R, Torrens M, et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol. 2013 Dec. 59(6):1184-92. [Medline].

  7. Laleman W, Simon-Talero M, Maleux G, et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013 Jun. 57(6):2448-57. [Medline].

  8. Albrecht J, Hilgier W, Rafalowska U. Activation of arginine metabolism to glutamate in rat brain synaptosomes in thioacetamide-induced hepatic encephalopathy: an adaptative response?. J Neurosci Res. 1990 Jan. 25(1):125-30. [Medline].

  9. Amaral OB, Quevedo J, Walz R, et al. Flumazenil and hepatic encephalopathy. Hepatology. 1999 Apr. 29(4):1338-9. [Medline].

  10. Amodio P, Del Piccolo F, Marchetti P, et al. Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology. 1999 Jun. 29(6):1662-7. [Medline].

  11. Avallone R, Zeneroli ML, Venturini I, et al. Endogenous benzodiazepine-like compounds and diazepam binding inhibitor in serum of patients with liver cirrhosis with and without overt encephalopathy. Gut. 1998 Jun. 42(6):861-7. [Medline].

  12. Bansky G, Meier PJ, Riederer E, et al. Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans. Gastroenterology. 1989 Sep. 97(3):744-50. [Medline].

  13. Barbaro G, Di Lorenzo G, Soldini M, et al. Flumazenil for hepatic coma in patients with liver cirrhosis: an Italian multicentre double-blind, placebo-controlled, crossover study. Eur J Emerg Med. 1998 Jun. 5(2):213-8. [Medline].

  14. Basile AS, Jones EA. Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology. 1997 Jun. 25(6):1303-5. [Medline].

  15. Bianchi GP, Marchesini G, Fabbri A, et al. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. J Intern Med. 1993 May. 233(5):385-92. [Medline].

  16. Bickford RG, Butt HR. Hepatic coma: the electroencephalographic pattern. J Clin Invest. 1955. 34:790-9.

  17. Bircher J, Buhrer M, Franz K, et al. [1st use of lactitol in the treatment of porto-systemic encephalopathy]. Schweiz Med Wochenschr. 1982 Sep 18. 112(38):1306-7. [Medline].

  18. Bresci G, Parisi G, Banti S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. Eur J Med. 1993 Aug-Sep. 2(7):414-6. [Medline].

  19. Butterworth RF. Pathogenesis of acute hepatic encephalopathy. Digestion. 1998 Jul. 59 Suppl 2:16-21. [Medline].

  20. Chan H, Hazell AS, Desjardins P. Neurotoxins generated in liver failure cause altered expression of genes coding for key astrocytic proteins. Hepatology. 1999. 30(4):234A.

  21. Charlton MR. Branched chains revisited. Gastroenterology. 1996 Jul. 111(1):252-5. [Medline].

  22. Child CG. Ligature of the portal vein (translation of original by Eck, 1877). Surg Gynecol Obstet. 1953. 375-6.

  23. Conn HO. Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis. 1977 Jun. 22(6):541-50. [Medline].

  24. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology. 1977 Apr. 72(4 Pt 1):573-83. [Medline].

  25. Costa E, Guidotti A. Diazepam binding inhibitor (DBI): a peptide with multiple biological actions. Life Sci. 1991. 49(5):325-44. [Medline].

  26. Córdoba J, Mínguez B. Hepatic encephalopathy. Semin Liver Dis. 2008 Feb. 28(1):70-80. [Medline].

  27. Dasani BM, Sigal SH, Lieber CS. Analysis of risk factors for chronic hepatic encephalopathy: the role of Helicobacter pylori infection. Am J Gastroenterol. 1998 May. 93(5):726-31. [Medline].

  28. de Bruijn KM, Blendis LM, Zilm DH, et al. Effect of dietary protein manipulation in subclinical portal-systemic encephalopathy. Gut. 1983 Jan. 24(1):53-60. [Medline].

  29. Deschenes M, Dufresne MP, Bui B, et al. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites. Am J Gastroenterol. 1999 May. 94(5):1361-5. [Medline].

  30. Eck NV. Ligature of the portal vein. Voen Med J St-Petersburg (Russo). 1877. 130:1-2.

  31. Elkington SG, Floch MH, Conn HO. Lactulose in the treatment of chronic portal-systemic encephalopathy. A double-blind clinical trial. N Engl J Med. 1969 Aug 21. 281(8):408-12. [Medline].

  32. Fabbri A, Magrini N, Bianchi G, et al. Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy. JPEN J Parenter Enteral Nutr. 1996 Mar-Apr. 20(2):159-64. [Medline].

  33. Felipo V, Hermenegildo C, Montoliu C, et al. Neurotoxicity of ammonia and glutamate: molecular mechanisms and prevention. Neurotoxicology. 1998 Aug-Oct. 19(4-5):675-81. [Medline].

  34. Ferenci P. Hepatic Encephalopathy. McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodes J, eds. Textbook of Clinical Hepatology. Oxford, England: Oxford University Press; 1991. Vol 1: 473-83.

  35. Fischer JE, Baldessarini RJ. False neurotransmitters and hepatic failure. Lancet. 1971 Jul 10. 2(7715):75-80. [Medline].

  36. Flannery DB, Hsia YE, Wolf B. Current status of hyperammonemic syndromes. Hepatology. 1982 Jul-Aug. 2(4):495-506. [Medline].

  37. Genesca J, Gonzalez A, Segura R, et al. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol. 1999 Jan. 94(1):169-77. [Medline].

  38. Germain L, Frexinos J, Louis A, et al. [Double blind study of lactulose in 8 patients with chronic hepatic encephalopathy after portocaval shunt]. Arch Fr Mal App Dig. 1973 Jun. 62(4):293-302. [Medline].

  39. Girard G, Butterworth RF. Effect of portacaval anastomosis on glutamine synthetase activities in liver, brain, and skeletal muscle. Dig Dis Sci. 1992 Jul. 37(7):1121-6. [Medline].

  40. Gitlin N. Hepatic encephalopathy. Zakim D, Boyer T, eds. Hepatology: a textbook of liver disease. 3rd ed. Philadelphia, Pa: WB Saunders; 1996. Vol 1: 605-17.

  41. Groeneweg M, Gyr K, Amrein R, et al. Effect of flumazenil on the electroencephalogram of patients with portosystemic encephalopathy. Results of a double blind, randomised, placebo-controlled multicentre trial. Electroencephalogr Clin Neurophysiol. 1996 Jan. 98(1):29-34. [Medline].

  42. Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology. 1993 Nov. 18(5):1139-43. [Medline].

  43. Hassanein TI, Tofteng F, Brown RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007 Dec. 46(6):1853-62. [Medline].

  44. Haussinger D, Laubenberger J, vom Dahl S, et al. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology. 1994 Nov. 107(5):1475-80. [Medline].

  45. Hazell AS, Desjardins P, Butterworth RF. Chronic exposure of rat primary astrocyte cultures to manganese results in increased binding sites for the 'peripheral-type' benzodiazepine receptor ligand 3H-PK 11195. Neurosci Lett. 1999 Aug 13. 271(1):5-8. [Medline].

  46. Howard ER. Encephalopathy without cirrhosis: hunt the shunt. Gut. 1999 Sep. 45(3):329-30. [Medline].

  47. Häussinger D. Hepatic glutamine transport and metabolism. Adv Enzymol Relat Areas Mol Biol. 1998. 72:43-86. [Medline].

  48. Häussinger D. Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology. 2006 Jun. 43(6):1187-90. [Medline].

  49. Ito S, Miyaji H, Azuma T, et al. Hyperammonaemia and Helicobacter pylori. Lancet. 1995 Jul 8. 346(8967):124-5. [Medline].

  50. Jalan R, Olde Damink SW, Hayes PC, et al. Diagnosis of hepatic encephalopathy: will in vivo proton MRS play a role?. Hepatology. 1999 May. 29(5):1605-7. [Medline].

  51. Jenkins RL, Gedaly R, Pomposelli JJ, et al. Distal splenorenal shunt: role, indications, and utility in the era of liver transplantation. Arch Surg. 1999 Apr. 134(4):416-20. [Medline].

  52. Kale RA, Gupta RK, Saraswat VA, et al. Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy. Hepatology. 2006 Apr. 43(4):698-706. [Medline].

  53. Keeling PW, Jones RB, Hilton PJ, et al. Reduced leucocyte zinc in liver disease. Gut. 1980 Jul. 21(7):561-4. [Medline].

  54. Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology. 1997 Jun. 25(6):1351-60. [Medline].

  55. Kircheis G, Quack G, Erbler H. L-ornithine L-aspartate in the treatment of hyperammonemia and hepatic encephalopathy. Conn HO, Bircher J, eds. Hepatic encephalopathy: syndromes and therapies. Bloomington, Ill: Medi-Ed; 1994. 373-83.

  56. Kullmann F, Hollerbach S, Holstege A, et al. Subclinical hepatic encephalopathy: the diagnostic value of evoked potentials. J Hepatol. 1995 Jan. 22(1):101-10. [Medline].

  57. Köstler H. Proton magnetic resonance spectroscopy in portal-systemic encephalopathy. Metab Brain Dis. 1998 Dec. 13(4):291-301. [Medline].

  58. Larsen FS, Ejlersen E, Clemmesen JO. Preservation of cerebral oxidative metabolism in fulminant hepatic failure: an autoregulation study. Liver Transpl Surg. 1996 Sep. 2(5):348-53. [Medline].

  59. Larsen FS, Olsen KS, Ejlersen E, et al. Cerebral blood flow autoregulation and transcranial Doppler sonography in patients with cirrhosis. Hepatology. 1995 Sep. 22(3):730-6. [Medline].

  60. Lata J, Hulek P, Fejfar T, et al. [Rifaximin in the treatment of hepatic encephalopathy]. Vnitr Lek. 2002 Jun. 48(6):578-82. [Medline].

  61. Laubenberger J, Haussinger D, Bayer S, et al. Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenterology. 1997 May. 112(5):1610-6. [Medline].

  62. Layrargues GP, Rose C, Spahr L, et al. Role of manganese in the pathogenesis of portal-systemic encephalopathy. Metab Brain Dis. 1998 Dec. 13(4):311-7. [Medline].

  63. Lee FY, Lu RH, Tsai YT, et al. Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic circulation. Scand J Gastroenterol. 1996 May. 31(5):500-5. [Medline].

  64. Lee JH, Seo DW, Lee YS, et al. Proton magnetic resonance spectroscopy (1H-MRS) findings for the brain in patients with liver cirrhosis reflect the hepatic functional reserve. Am J Gastroenterol. 1999 Aug. 94(8):2206-13. [Medline].

  65. Lockwood AH. Early detection and treatment of hepatic encephalopathy. Curr Opin Neurol. 1998 Dec. 11(6):663-6. [Medline].

  66. Lockwood AH, Yap EW, Rhoades HM, et al. Altered cerebral blood flow and glucose metabolism in patients with liver disease and minimal encephalopathy. J Cereb Blood Flow Metab. 1991 Mar. 11(2):331-6. [Medline].

  67. Lockwood AH, Yap EW, Wong WH. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab. 1991 Mar. 11(2):337-41. [Medline].

  68. Loguercio C, Abbiati R, Rinaldi M, et al. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol. 1995 Jul. 23(1):39-46. [Medline].

  69. Manzoni O, Prezeau L, Marin P, et al. Nitric oxide-induced blockade of NMDA receptors. Neuron. 1992 Apr. 8(4):653-62. [Medline].

  70. Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003 Jan. 38(1):51-8. [Medline].

  71. Mehndiratta MM, Sood GK, Sarin SK, et al. Comparative evaluation of visual, somatosensory, and auditory evoked potentials in the detection of subclinical hepatic encephalopathy in patients with nonalcoholic cirrhosis. Am J Gastroenterol. 1990 Jul. 85(7):799-803. [Medline].

  72. Mendenhall CL, Rouster S, Marshall L, et al. A new therapy for portal systemic encephalopathy. Am J Gastroenterol. 1986 Jul. 81(7):540-3. [Medline].

  73. Michalopoulos GK, DeFrances MC. Liver regeneration. Science. 1997 Apr 4. 276(5309):60-6. [Medline].

  74. Montague PR, Gancayco CD, Winn MJ, et al. Role of NO production in NMDA receptor-mediated neurotransmitter release in cerebral cortex. Science. 1994 Feb 18. 263(5149):973-7. [Medline].

  75. Moore JW, Dunk AA, Crawford JR, et al. Neuropsychological deficits and morphological MRI brain scan abnormalities in apparently healthy non-encephalopathic patients with cirrhosis. A controlled study. J Hepatol. 1989 Nov. 9(3):319-25. [Medline].

  76. Moorman AF, Vermeulen JL, Charles R, et al. Localization of ammonia-metabolizing enzymes in human liver: ontogenesis of heterogeneity. Hepatology. 1989 Mar. 9(3):367-72. [Medline].

  77. Morgan MH, Read AE, Speller DC. Treatment of hepatic encephalopathy with metronidazole. Gut. 1982 Jan. 23(1):1-7. [Medline].

  78. Morgan MY. Cerebral magnetic resonance imaging in patients with chronic liver disease. Metab Brain Dis. 1998 Dec. 13(4):273-90. [Medline].

  79. Morgan MY, Jakobovits AW, James IM, et al. Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. Gastroenterology. 1980 Apr. 78(4):663-70. [Medline].

  80. Mullen KD, Szauter KM, Kaminsky-Russ K. "Endogenous" benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet. 1990 Jul 14. 336(8707):81-3. [Medline].

  81. Ong J, Kerr DI. Clinical potential of GABAB receptor modulators. CNS Drug Rev. 2005 Autumn. 11(3):317-34. [Medline].

  82. Perney P, Butterworth RF, Mousseau DD, et al. Plasma and CSF benzodiazepine receptor ligand concentrations in cirrhotic patients with hepatic encephalopathy: relationship to severity of encephalopathy and to pharmaceutical benzodiazepine intake. Metab Brain Dis. 1998 Sep. 13(3):201-10. [Medline].

  83. Pogun S, Dawson V, Kuhar MJ. Nitric oxide inhibits 3H-glutamate transport in synaptosomes. Synapse. 1994 Sep. 18(1):21-6. [Medline].

  84. Pomier-Layrargues G. TIPS and hepatic encephalopathy. Semin Liver Dis. 1996 Aug. 16(3):315-20. [Medline].

  85. Pomier-Layrargues G, Giguere JF, Lavoie J, et al. Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial. Hepatology. 1994 Jan. 19(1):32-7. [Medline].

  86. Quero JC, Hartmann IJ, Meulstee J, et al. The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis. Hepatology. 1996 Sep. 24(3):556-60. [Medline].

  87. Rao VL, Butterworth RF. Neuronal nitric oxide synthase and Hepatic Encephalopathy. Metab Brain Dis. 1998 Sep. 13(3):175-89. [Medline].

  88. Read AE, McCarthy CF, Heaton KW, et al. Lactobacillus acidophilus (enpac) in treatment of hepatic encephalopathy. Br Med J. 1966 May 21. 1(5498):1267-9. [Medline].

  89. Riggio O, Efrati C, Catalano C, et al. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology. 2005 Nov. 42(5):1158-65. [Medline].

  90. Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol. 2005 May. 42(5):674-9. [Medline].

  91. Riggio O, Merlli M, Pedretti G, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. Dig Dis Sci. 1996 Mar. 41(3):578-84. [Medline].

  92. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med. 1997 Aug 14. 337(7):473-9. [Medline].

  93. Rose C, Butterworth RF, Zayed J, et al. Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology. 1999 Sep. 117(3):640-4. [Medline].

  94. Rose C, Michalak A, Pannunzio P, et al. L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis. 1998 Jun. 13(2):147-57. [Medline].

  95. Sandford SL, Tarter RE, Sclabassi R, et al. Sensory information processing in patients with nonalcoholic cirrhosis. Short-latency visual, auditory, and somatosensory event-related potentials. J Neurol Sci. 1987 Sep. 80(2-3):269-76. [Medline].

  96. Sanyal AJ, Freedman AM, Shiffman ML, et al. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology. 1994 Jul. 20(1 Pt 1):46-55. [Medline].

  97. Schumacher IK, Okamoto T, Kim BH, et al. Transplantation of conditionally immortalized hepatocytes to treat hepatic encephalopathy. Hepatology. 1996 Aug. 24(2):337-43. [Medline].

  98. Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol. 1998 May. 28(5):856-64. [Medline].

  99. Strauss E, Tramote R, Silva EP, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology. 1992 Dec. 39(6):542-5. [Medline].

  100. Sushma S, Dasarathy S, Tandon RK, et al. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology. 1992 Jul. 16(1):138-44. [Medline].

  101. Taylor-Robinson SD, Oatridge A, Hajnal JV, et al. MR imaging of the basal ganglia in chronic liver disease: correlation of T1-weighted and magnetisation transfer contrast measurements with liver dysfunction and neuropsychiatric status. Metab Brain Dis. 1995 Jun. 10(2):175-88. [Medline].

  102. Unseld E, Krishna DR, Fischer C, et al. Detection of desmethyldiazepam and diazepam in brain of different species and plants. Biochem Pharmacol. 1989 Aug 1. 38(15):2473-8. [Medline].

  103. Uribe M, García-Ramos G, Ramos M, et al. Standard and higher doses of bromocriptine for severe chronic portal-systemic encephalopathy. Am J Gastroenterol. 1983 Aug. 78(8):517-22. [Medline].

  104. Van der Rijt CC, Schalm SW, De Groot GH, et al. Objective measurement of hepatic encephalopathy by means of automated EEG analysis. Electroencephalogr Clin Neurophysiol. 1984 May. 57(5):423-6. [Medline].

  105. Weissenborn K, Kolbe H. The basal ganglia and portal-systemic encephalopathy. Metab Brain Dis. 1998 Dec. 13(4):261-72. [Medline].

  106. Weissenborn K, Scholz M, Hinrichs H, et al. Neurophysiological assessment of early hepatic encephalopathy. Electroencephalogr Clin Neurophysiol. 1990 Apr. 75(4):289-95. [Medline].

  107. Yen CL, Liaw YF. Somatosensory evoked potentials and number connection test in the detection of subclinical hepatic encephalopathy. Hepatogastroenterology. 1990 Jun. 37(3):332-4. [Medline].

  108. Yurdaydin C, Karavelioglu D, Onaran O, et al. Opioid receptor ligands in human hepatic encephalopathy. J Hepatol. 1998 Nov. 29(5):796-801. [Medline].

  109. Zullo A, Rinaldi V, Meddi P, et al. Helicobacter pylori infection, plasma ammonia levels, and psychometric testing in cirrhotic patients. Am J Gastroenterol. 1999 Aug. 94(8):2214-8. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.